$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000159075017000010 Filed on November 09, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$1.192M	$1.631M	$936.0K
YoY Change	134.18%	74.25%	-29.89%
Cost Of Revenue			$599.0K
YoY Change			3.81%
Gross Profit			$337.0K
YoY Change			-55.54%
Gross Profit Margin			36.0%
Selling, General & Admin	$2.550M	$2.500M	$2.426M
YoY Change	1.19%	3.05%	-13.33%
% of Gross Profit			719.88%
Research & Development	$4.998M	$5.018M	$2.965M
YoY Change	27.96%	69.24%	1071.94%
% of Gross Profit			879.82%
Depreciation & Amortization	$80.00K	$100.0K	$100.0K
YoY Change	-60.0%	0.0%	100.0%
% of Gross Profit			29.67%
Operating Expenses	$4.998M	$7.520M	$5.018M
YoY Change	27.96%	49.86%	38.28%
Operating Profit		-$5.889M	-$4.082M
YoY Change		44.27%	30.5%
Interest Expense	-$30.00K	$60.00K	$23.00K
YoY Change	-50.0%	160.87%	-4.17%
% of Operating Profit
Other Income/Expense, Net	-$32.00K	$113.0K	$7.000K
YoY Change	-46.67%	1514.29%
Pretax Income	-$6.390M	-$5.830M	-$4.150M
YoY Change	7.04%	40.48%	31.75%
Income Tax
% Of Pretax Income
Net Earnings	-$6.386M	-$5.834M	-$4.153M
YoY Change	6.9%	40.48%	31.76%
Net Earnings / Revenue	-535.74%	-357.69%	-443.7%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.289M	-$4.049M	-$103.8M
COMMON SHARES
Basic Shares Outstanding	22.31M shares	21.48M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$47.40M	$42.80M	$5.400M
YoY Change	114.48%	692.59%	-55.37%
Cash & Equivalents	$47.44M	$42.81M	$24.60M
Short-Term Investments
Other Short-Term Assets	$3.000M	$3.000M	$400.0K
YoY Change	66.67%	650.0%	-33.33%
Inventory			$62.00K
Prepaid Expenses
Receivables	$1.456M	$635.0K	$733.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$51.87M	$46.42M	$6.512M
YoY Change	117.23%	612.85%	-52.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$563.0K	$610.0K	$1.014M
YoY Change	-9.92%	-39.84%	-13.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$0.00
YoY Change	-80.62%
Total Long-Term Assets	$613.0K	$660.0K	$1.029M
YoY Change	-30.58%	-35.86%	-13.67%
TOTAL ASSETS
Total Short-Term Assets	$51.87M	$46.42M	$6.512M
Total Long-Term Assets	$613.0K	$660.0K	$1.029M
Total Assets	$52.48M	$47.08M	$7.541M
YoY Change	111.96%	524.33%	-49.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$906.0K	$409.0K	$51.00K
YoY Change	-10.03%	701.96%	-73.85%
Accrued Expenses	$2.991M	$4.142M	$1.649M
YoY Change	-23.48%	151.18%	131.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$1.100M
YoY Change		-100.0%	0.0%
Long-Term Debt Due	$0.00	$2.000M
YoY Change	-100.0%
Total Short-Term Liabilities	$3.897M	$6.534M	$2.853M
YoY Change	-43.4%	129.02%	34.96%
LONG-TERM LIABILITIES
Long-Term Debt	$9.900M	$1.400M	$0.00
YoY Change	253.57%
Other Long-Term Liabilities	$152.0K	$171.0K	$2.000K
YoY Change		8450.0%	-96.0%
Total Long-Term Liabilities	$152.0K	$171.0K	$2.000K
YoY Change		8450.0%	-96.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.897M	$6.534M	$2.853M
Total Long-Term Liabilities	$152.0K	$171.0K	$2.000K
Total Liabilities	$13.97M	$8.096M	$2.855M
YoY Change	43.96%	183.57%	31.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.59M	-$87.21M	-$25.07M
YoY Change	39.53%	247.83%	67.28%
Common Stock	$226.0K	$219.0K	$108.0K
YoY Change	2725.0%	102.78%	1.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$38.51M	$38.99M	$4.686M
YoY Change
Total Liabilities & Shareholders Equity	$52.48M	$47.08M	$7.541M
YoY Change	111.96%	524.33%	-49.04%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$6.386M	-$5.834M	-$4.153M
YoY Change	6.9%	40.48%	31.76%
Depreciation, Depletion And Amortization	$80.00K	$100.0K	$100.0K
YoY Change	-60.0%	0.0%	100.0%
Cash From Operating Activities	-$7.250M	-$5.660M	-$1.120M
YoY Change	-22.95%	405.36%	-51.3%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$60.00K	$0.00
YoY Change	-84.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$40.00K	-$60.00K	$0.00
YoY Change	-84.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.91M	2.200M	-20.00K
YoY Change	-25.52%	-11100.0%	-100.5%
NET CHANGE
Cash From Operating Activities	-7.250M	-5.660M	-1.120M
Cash From Investing Activities	-40.00K	-60.00K	0.000
Cash From Financing Activities	11.91M	2.200M	-20.00K
Net Change In Cash	4.620M	-3.520M	-1.140M
YoY Change	-27.01%	208.77%	-167.46%
FREE CASH FLOW
Cash From Operating Activities	-$7.250M	-$5.660M	-$1.120M
Capital Expenditures	-$40.00K	-$60.00K	$0.00
Free Cash Flow	-$7.210M	-$5.600M	-$1.120M
YoY Change	-21.29%	400.0%	-50.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	mgen	Accretionof Offering Costs AccretionofOfferingCosts	37000	USD
	mgen	Accretionof Offering Costs AccretionofOfferingCosts	5000	USD
CY2016Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	759000	USD
CY2017Q3	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	607000	USD
CY2016Q4	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	0	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q3	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	156000	USD
CY2016Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	133000	USD
CY2017Q3	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2016Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1684000	USD
CY2017Q3	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1635000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22309419	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	MIRAGEN THERAPEUTICS, INC.
	mgen	Transferof Stock Issuance Costs Noncashor Partial Noncash Transaction TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction	339000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	545000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	719000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4142000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	124000	USD
CY2017Q3	mgen	Accumulated Amortization Deferred Costs AccumulatedAmortizationDeferredCosts	8000	USD
	mgen	Adjustmentsto Additional Paidin Capital Reclassificationof Warrant Liability AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability	51000	USD
CY2017Q3	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	105000000	shares
	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	0	USD
	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	51000	USD
CY2016Q4	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	167000	USD
CY2017Q3	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	227000	USD
CY2016Q3	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
CY2017Q3	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
CY2017Q3	mgen	Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding	908227	shares
	mgen	Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	0	USD
	mgen	Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	3000	USD
	mgen	Transferof Stock Issuance Costs Noncashor Partial Noncash Transaction TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction	0	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1007000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	409000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	635000	USD
	us-gaap	Accretion Expense AccretionExpense	125000	USD
	us-gaap	Accretion Expense AccretionExpense	85000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3909000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	457000	USD
CY2016Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	221000	USD
CY2017Q3	us-gaap	Accrued Rent Current AccruedRentCurrent	70000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2558000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2776000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5147000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125973000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1693000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	400000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	129000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	679000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1693000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15365000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2994000	shares
CY2016Q4	us-gaap	Assets Assets	24760000	USD
CY2017Q3	us-gaap	Assets Assets	47081000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	23877000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	46421000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1280000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21235000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24598000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22104000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42805000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	3363000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	20701000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	773067	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	833744	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21886568	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	833744	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21886568	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	219000	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4667000	USD
CY2017Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3167000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	14000	USD
CY2017Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	6000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	31000	USD
CY2017Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	14000	USD
CY2017Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	100000	USD
CY2016Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	253000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
CY2017Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	227000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.92
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-18.84
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	928000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1061000	USD
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7400000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M11D
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	51000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	133000	USD
CY2017Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	82000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2053000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4255000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-439000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2017Q3	us-gaap	Liabilities Liabilities	8096000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24760000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2502000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8364000	USD
CY2016Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2017Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2016Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2017Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-586000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-598000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	615000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	893000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-871000	USD
CY2016Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	78000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	250000	USD
CY2017Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	58000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	193000	USD
	us-gaap	Interest Paid InterestPaid	124000	USD
	us-gaap	Interest Paid InterestPaid	112000	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	9705000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47081000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6885000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6534000	USD
CY2016Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	715000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2479000	USD
CY2017Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1493000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1991000	USD
CY2017Q3	us-gaap	Long Term Debt LongTermDebt	3167000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	667000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2000000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	500000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2820000	USD
CY2017Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	1391000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments	-9000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16081000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40557000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1250000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1068000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11468000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20924000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-4153000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11300000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5834000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20126000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4166000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11337000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5834000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20131000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	1076000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	23000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	113000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	245000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	4789000	USD
CY2017Q3	us-gaap	Notes Payable NotesPayable	3374000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1969000	USD
CY2017Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1983000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	5018000	USD
	us-gaap	Operating Expenses OperatingExpenses	14041000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	7520000	USD
	us-gaap	Operating Expenses OperatingExpenses	22989000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4082000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11073000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5889000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20178000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1167000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	277000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	404000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	391000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	95000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	60000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	74000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	258000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	171000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1010000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	240000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	212000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1693000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	204000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	5000	USD
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1753000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2981000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40700000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	16091000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	0	USD
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	110000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	220000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3183000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3386000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	625000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	610000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	0	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	76981000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1500000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2965000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9786000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5018000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14625000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67076000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87207000	USD
CY2016Q3	us-gaap	Revenue From Grants RevenueFromGrants	221000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	489000	USD
CY2017Q3	us-gaap	Revenue From Grants RevenueFromGrants	138000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	820000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	936000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2968000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1631000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2811000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	129000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	110000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	220000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-61921000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	38985000	USD
CY2016Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	13000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	37000	USD
CY2017Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	5000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	601667	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	601667	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21572498	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18215857	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with two financial institutions.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001590750-17-000010-index-headers.html	Edgar Link	pending
0001590750-17-000010-index.html	Edgar Link	pending
0001590750-17-000010.txt	Edgar Link	pending
0001590750-17-000010-xbrl.zip	Edgar Link	pending
a102yaletouploadctr.htm	Edgar Link	pending
a102yaletouploadctr001.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mgen-20170930.xml	Edgar Link	completed
mgen-20170930.xsd	Edgar Link	pending
mgen-20170930_cal.xml	Edgar Link	unprocessable
mgen-20170930_def.xml	Edgar Link	unprocessable
mgen-20170930_lab.xml	Edgar Link	unprocessable
mgen-20170930_pre.xml	Edgar Link	unprocessable
mgen-9302017x10q.htm	Edgar Link	pending
mgen-9302017xex102servier.htm	Edgar Link	pending
mgen-9302017xex311.htm	Edgar Link	pending
mgen-9302017xex312.htm	Edgar Link	pending
mgen-9302017xex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2017 Q4 Form 10-Q Financial Statement

#000159075017000010 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2017 Q4 Form 10-Q Financial Statement

#000159075017000010 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn